Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA E418K PIK3CA E453K |
| Therapy | Everolimus + MK2206 |
| Indication/Tumor Type | breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA E418K PIK3CA E453K | breast cancer | sensitive | Everolimus + MK2206 | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with the combination of MK2206 and Afinitor (everolimus) synergistically inhibited proliferation, decreased Akt phosphorylation, and increased apoptosis in a breast cancer cell line harboring PIK3CA E418K and E453K in culture (PMID: 38909932). | 38909932 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38909932) | Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells. | Full reference... |